

1. Physicochemical Property

| Property | Value | Comment |
|------------------|---------|--|
| Molecular Weight | 332.2 | Contain hydrogen atoms. Optimal:100~600 |
| Volume | 353.422 | Van der Waals volume |
| Density | 0.94 | Density = MW / Volume |
| nHA | 4 | Number of hydrogen bond acceptors. Optimal:0~12 |
| nHD | 3 | Number of hydrogen bond donors. Optimal:0~7 |
| nRot | 2 | Number of rotatable bonds. Optimal:0~11 |
| nRing | 3 | Number of rings. Optimal:0~6 |
| MaxRing | 14 | Number of atoms in the biggest ring. Optimal:0~18 |
| nHet | 4 | Number of heteroatoms. Optimal:1~15 |
| fChar | 0 | Formal charge. Optimal:-4 ~4 |
| nRig | 17 | Number of rigid bonds. Optimal:0~30 |
| Flexibility | 0.118 | Flexibility = nRot /nRig |
| Stereo Centers | 2 | Optimal: ≤ 2 |
| TPSA | 77.76 | Topological Polar Surface Area. Optimal:0~140 |
| logS | -3.739 | Log of the aqueous solubility. Optimal: -4~0.5 log mol/L |
| logP | 4.165 | Log of the octanol/water partition coefficient. Optimal: 0~3 |
| logD | 2.923 | logP at physiological pH 7.4. Optimal: 1~3 |

2. Medicinal Chemistry

| Property | Value | Decision | Comment |
|----------|--------|----------|--|
| QED | 0.705 | | ■ A measure of drug-likeness based on the concept of desirability; ■ Attractive: > 0.67; unattractive: 0.49~0.67; too complex: < 0.34 |
| SAscore | 3.768 | • | ■ Synthetic accessibility score is designed to estimate ease of synthesis of drug-like molecules. ■ SAscore ≥ 6, difficult to synthesize; SAscore <6, easy to synthesize |
| Fsp3 | 0.65 | • | ■ The number of sp3 hybridized carbons / total carbon count, correlating with melting point and solubility. ■ Fsp³ ≥0.42 is considered a suitable value. |
| MCE-18 | 80.152 | • | ■ MCE-18 stands for medicinal chemistry evolution.■ MCE-18≥45 is considered a suitable value. |

| NPscore | 2.171 | - | ■ Natural product-likeness score. ■ This score is typically in the range from –5 to 5. The higher the score is, the higher the probability is that the molecule is a NP. |
|--------------------|----------|---|--|
| Lipinski Rule | Accepted | • | ■ MW ≤ 500; logP ≤ 5; Hacc ≤ 10; Hdon ≤ 5 ■ If two properties are out of range, a poor absorption or permeability is possible, one is acceptable. |
| Pfizer Rule | Accepted | • | logP > 3; TPSA < 75 Compounds with a high log P (>3) and low TPSA (<75) are likely to be toxic. |
| GSK Rule | Rejected | • | ■ MW ≤ 400; logP ≤ 4 ■ Compounds satisfying the GSK rule may have a more favorable ADMET profile |
| Golden Triangle | Accepted | • | ■ 200 ≤ MW ≤ 50; -2 ≤ logD ≤ 5 ■ Compounds satisfying the Golden Triangle rule may have a more favorable ADMET profile. |
| PAINS | 1 alerts | - | Pan Assay Interference Compounds, frequent hitters, Alpha-screen artifacts and reactive compound. |
| ALARM NMR | 1 alerts | - | Thiol reactive compounds. |
| BMS | 0 alerts | - | Undesirable, reactive compounds. |
| Chelator Rule | 1 alerts | - | Chelating compounds. |

3. Absorption

| Property | Value | Decision | Comment |
|------------------------|---------|----------|--|
| Caco-2 Permeability | -4.802 | • | Optimal: higher than -5.15 Log unit |
| MDCK Permeability | 2.3e-05 | • | ■ low permeability: < 2 x 10⁻⁶ cm/s ■ medium permeability: 2-20 x 10⁻⁶ cm/s ■ high passive permeability: > 20 x 10⁻⁶ cm/s |
| Pgp-inhibitor | 0.025 | | ■ Category 1: Inhibitor; Category 0: Non-inhibitor; ■ The output value is the probability of being Pgp-inhibitor |
| Pgp-substrate | 0.001 | • | ■ Category 1: substrate; Category 0: Non-substrate; ■ The output value is the probability of being Pgp-substrate |
| НІА | 0.011 | • | ■ Human Intestinal Absorption ■ Category 1: HIA+(HIA < 30%); Category 0: HIA-(HIA < 30%); The output value is the probability of being HIA+ |
| F _{20%} | 0.861 | • | ■ 20% Bioavailability ■ Category 1: $F_{20\%}$ + (bioavailability < 20%); Category 0: $F_{20\%}$ - (bioavailability ≥ 20%); The output value is the probability of being $F_{20\%}$ + |

| F _{30%} | 0.905 | • | ■ 30% Bioavailability ■ Category 1: $F_{30\%}$ + (bioavailability < 30%); Category 0: $F_{30\%}$ - (bioavailability ≥ 30%); The output value is the probability of being $F_{30\%}$ + |
|------------------|-------|---|---|
|------------------|-------|---|---|

4. Distribution

| Property | Value | Decision | Comment |
|--------------------|--------|----------|---|
| PPB | 99.51% | • | ■ Plasma Protein Binding■ Optimal: < 90%. Drugs with high protein-bound may have a low therapeutic index. |
| VD | 0.608 | • | ■ Volume Distribution ■ Optimal: 0.04-20L/kg |
| BBB Penetration | 0.319 | • | ■ Blood-Brain Barrier Penetration ■ Category 1: BBB+; Category 0: BBB-; The output value is the probability of being BBB+ |
| Fu | 1.808% | • | ■ The fraction unbound in plasms ■ Low: <5%; Middle: 5~20%; High: > 20% |

5. Metabolism

| Property | Value | Comment |
|----------------------|-------|---|
| CYP1A2 inhibitor | 0.054 | ■ Category 1: Inhibitor; Category 0: Non-inhibitor; ■ The output value is the probability of being inhibitor. |
| CYP1A2 substrate | 0.781 | ■ Category 1: Substrate; Category 0: Non-substrate; ■ The output value is the probability of being substrate. |
| CYP2C19 inhibitor | 0.017 | ■ Category 1: Inhibitor; Category 0: Non-inhibitor; ■ The output value is the probability of being inhibitor. |
| CYP2C19 substrate | 0.8 | ■ Category 1: Substrate; Category 0: Non-substrate; ■ The output value is the probability of being substrate. |
| CYP2C9 inhibitor | 0.315 | ■ Category 1: Inhibitor; Category 0: Non-inhibitor; ■ The output value is the probability of being inhibitor. |
| CYP2C9 substrate | 0.787 | ■ Category 1: Substrate; Category 0: Non-substrate; ■ The output value is the probability of being substrate. |
| CYP2D6 inhibitor | 0.029 | ■ Category 1: Inhibitor; Category 0: Non-inhibitor; ■ The output value is the probability of being inhibitor. |
| CYP2D6 substrate | 0.205 | ■ Category 1: Substrate; Category 0: Non-substrate; ■ The output value is the probability of being substrate. |
| CYP3A4 inhibitor | 0.041 | ■ Category 1: Inhibitor; Category 0: Non-inhibitor; ■ The output value is the probability of being inhibitor. |
| CYP3A4 substrate | 0.13 | ■ Category 1: Substrate; Category 0: Non-substrate; ■ The output value is the probability of being substrate. |

6. Excretion

| Property | Value | Decision | Comment |
|------------------|-------|----------|--|
| CL | 0.494 | • | ■ Clearance ■ High: >15 mL/min/kg; moderate: 5-15 mL/min/kg; low: <5 mL/min/kg |
| T _{1/2} | 0.488 | - | ■ Category 1: long half-life; Category 0: short half-life; ■ long half-life: >3h; short half-life: <3h ■ The output value is the probability of having long half-life. |

7. Toxicity

| Property | Value | Decision | Comment |
|-------------------------------|-------|----------|--|
| hERG Blockers | 0.003 | • | ■ Category 1: active; Category 0: inactive; ■ The output value is the probability of being active. |
| H-HT | 0.142 | • | ■ Human Hepatotoxicity ■ Category 1: H-HT positive(+); Category 0: H-HT negative(-); ■ The output value is the probability of being toxic. |
| DILI | 0.022 | • | ■ Drug Induced Liver Injury. ■ Category 1: drugs with a high risk of DILI; Category 0: drugs with no risk of DILI. The output value is the probability of being toxic. |
| AMES Toxicity | 0.035 | • | ■ Category 1: Ames positive(+); Category 0: Ames negative(-);■ The output value is the probability of being toxic. |
| Rat Oral Acute Toxicity | 0.212 | • | ■ Category 0: low-toxicity; Category 1: high-toxicity; ■ The output value is the probability of being highly toxic. |
| FDAMDD | 0.521 | | ■ Maximum Recommended Daily Dose ■ Category 1: FDAMDD (+); Category 0: FDAMDD (-) ■ The output value is the probability of being positive. |
| Skin Sensiti zation | 0.902 | • | ■ Category 1: Sensitizer; Category 0: Non-sensitizer; ■ The output value is the probability of being sensitizer. |
| Carcinogen city | 0.067 | • | ■ Category 1: carcinogens; Category 0: non-carcinogens;■ The output value is the probability of being toxic. |
| Eye Corrosion | 0.004 | • | ■ Category 1: corrosives ; Category 0: noncorrosives ■ The output value is the probability of being corrosives. |
| Eye Irritation | 0.889 | • | ■ Category 1: irritants; Category 0: nonirritants ■ The output value is the probability of being irritants. |

| Respiratory Toxicity | 0.563 | • | ■ Category 1: respiratory toxicants; Category 0: respiratory nontoxicants ■ The output value is the probability of being toxic. |
|-------------------------|-------|---|---|
|-------------------------|-------|---|---|

8. Environmental toxicity

| Property | Value | Comment | |
|-----------------------------|-------|---|--|
| Bioconcentration Factors | 0.945 | ■ Bioconcentration factors are used for considering secondary poisoning potential and assessing risks to human health via the food chain. ■ The unit is -log10[(mg/L)/(1000*MW)] | |
| IGC ₅₀ | 4.381 | ■ Tetrahymena pyriformis 50 percent growth inhibition concentration ■ The unit is -log10[(mg/L)/(1000*MW)] | |
| LC ₅₀ FM | 4.573 | ■ 96-hour fathead minnow 50 percent lethal concentration ■ The unit is -log10[(mg/L)/(1000*MW)] | |
| LC ₅₀ DM | 5.604 | ■ 48-hour daphnia magna 50 percent lethal concentration ■ The unit is -log10[(mg/L)/(1000*MW)] | |

9. Tox21 pathway

| Property | Value | Decision | Comment |
|-------------------|-------|----------|---|
| NR-AR | 0.44 | • | ■ Androgen receptor ■ Category 1: actives; Category 0: inactives; ■ The output value is the probability of being active. |
| NR-AR-LBD | 0.011 | • | Androgen receptor ligand-binding domain Category 1: actives; Category 0: inactives; The output value is the probability of being active. |
| NR-AhR | 0.204 | • | ■ Aryl hydrocarbon receptor ■ Category 1: actives; Category 0: inactives; ■ The output value is the probability of being active. |
| NR-Aromatase | 0.349 | • | ■ Category 1: actives; Category 0: inactives; ■ The output value is the probability of being active. |
| NR-ER | 0.596 | • | ■ Estrogen receptor ■ Category 1: actives; Category 0: inactives; ■ The output value is the probability of being active. |
| NR-ER-LBD | 0.255 | | ■ Estrogen receptor ligand-binding domain ■ Category 1: actives; Category 0: inactives; ■ The output value is the probability of being active. |
| NR-PPAR- gamma | 0.964 | • | ■ Peroxisome proliferator-activated receptor gamma ■ Category 1: actives; Category 0: inactives; ■ The output value is the probability of being active. |
| SR-ARE | 0.64 | • | ■ Antioxidant response element ■ Category 1: actives; Category 0: inactives; ■ The output value is the probability of being active. |
| SR-ATAD5 | 0.036 | • | ■ ATPase family AAA domain-containing protein 5 ■ Category 1: actives; Category 0: inactives; ■ The output value is the probability of being active. |

| SR-HSE | 0.843 | • | ■ Heat shock factor response element ■ Category 1: actives; Category 0: inactives; ■ The output value is the probability of being active. |
|--------|-------|---|---|
| SR-MMP | 0.879 | • | ■ Mitochondrial membrane potential ■ Category 1: actives; Category 0: inactives; ■ The output value is the probability of being active. |
| SR-p53 | 0.863 | • | ■ Category 1: actives; Category 0: inactives; ■ The output value is the probability of being active. |

10. Toxicophore Rules

| Property | Value | Comment |
|---|----------|--|
| Acute Toxicity Rule | 0 alerts | ■ 20 substructures■ acute toxicity during oral administration |
| Genotoxic Carcinogenicity Rule | 0 alerts | ■ 117 substructures ■ carcinogenicity or mutagenicity |
| NonGenotoxic Carcinogenicity Rule | 0 alerts | ■ 23 substructures ■ carcinogenicity through nongenotoxic mechanisms |
| Skin Sensitization Rule | 5 alerts | ■ 155 substructures ■ skin irritation |
| Aquatic Toxicity Rule | 0 alerts | ■ 99 substructures ■ toxicity to liquid(water) |
| NonBiodegradable Rule | 1 alerts | ■ 19 substructures ■ non-biodegradable |
| SureChEMBL Rule | 1 alerts | ■ 164 substructures■ MedChem unfriendly status |